You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗股下跌 藥明生物(02269.HK)及三葉草(02197.HK)挫6%及17%
阿思達克 11-22 15:23
歐洲近期疫情持續嚴峻,區內新增確診病例再度激增,奧地利率先宣在重啓全面封城措施,新增確診宗數屢創紀錄高的德國也不排除重施封城可能性。疫苗股莫德納(MRNA.US)及BioNTech(BNTX.US)上週五分別漲4.9%及5.7%收263.78美元及289.75美元。 然而,本港上市疫苗股今天普遍受壓,尤其是本月5日才以每股13.38元上市的三葉草生物-B(02197.HK)上週四收市後公佈新冠候選疫苗獲追加最多3,690萬美元額外預算,股價繼上週五續升至13.14元(受制首掛日所創高位13.56元)後,今天股價低見10.56元,現報10.72元,瀉17%,考驗10天線(10.72元)支持。 康希諾生物-B(06185.HK)四連跌,最低見157元,暫守穩本月初所創低位153元,現報157.6元,續跌3.4%。復星醫藥(02196.HK)曾一舉失守10天及50天線(39.4元及40.05元),最低見39元,現報39.35元,回吐4.5%。 騰盛博藥-B(02137.HK)由個半月高位反覆連吐第二天,今天高低見38元/34.8元,現報35.95元,反覆續跌1.2%。上週初據報騰盛博藥旗下騰盛華創與清華大學和深圳市第三人民醫院共同研發的中和抗體聯合療法已於10月9日向國家藥監局提交附條件上市申報材料,並有望12月底前獲批,消息刺激騰盛博藥股價累飆逾65%。 開拓藥業-B(09939.HK)反覆三連跌,今天高低見62元/58.65元,現報58.65元,續跌1.6%。 藍籌藥明生物(02269.HK)三連跌,今早股價高開逾1%報112元欠承接,掉頭輾轉滑落兼一舉失守110天、20天及牛熊線(107.5-110.25元),午後初段低見104元,現報104.1元,續挫5.9%。 此外,藥明康德(02359.HK)也三連跌,今早股價高開報158.8元欠承接,掉頭低見153.7元,現報155.1元,續跌2%。 將於下月6日起取代中國恆大(03333.HK)成爲國指成份股的信達生物(01801.HK)承上週五升勢,今早高見82元無以爲繼,掉頭失守10天及牛熊線(77.8元及75.15元),最低見75.5元,現報76.9元,倒跌4.2%。 海吉亞醫療(06078.HK)反覆失守20天及10天線(66.95元及69.14元),現報66.75元,跌5.3%;微創醫療(00853.HK)四連跌,最低見34.85元,現報35.1元,挫6.9%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account